[go: up one dir, main page]

WO2007095032A3 - Mutations and polymorphisms of ptk2b - Google Patents

Mutations and polymorphisms of ptk2b Download PDF

Info

Publication number
WO2007095032A3
WO2007095032A3 PCT/US2007/003280 US2007003280W WO2007095032A3 WO 2007095032 A3 WO2007095032 A3 WO 2007095032A3 US 2007003280 W US2007003280 W US 2007003280W WO 2007095032 A3 WO2007095032 A3 WO 2007095032A3
Authority
WO
WIPO (PCT)
Prior art keywords
ptk2b
mutations
mutant
polymorphisms
various aspects
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2007/003280
Other languages
French (fr)
Other versions
WO2007095032A2 (en
Inventor
Kenneth Wayne Culver
Jian Zhu
Stan Lilleberg
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis Pharma GmbH Austria
Novartis AG
Original Assignee
Novartis Pharma GmbH Austria
Novartis AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Pharma GmbH Austria, Novartis AG filed Critical Novartis Pharma GmbH Austria
Publication of WO2007095032A2 publication Critical patent/WO2007095032A2/en
Publication of WO2007095032A3 publication Critical patent/WO2007095032A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • C12N9/1205—Phosphotransferases with an alcohol group as acceptor (2.7.1), e.g. protein kinases
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/172—Haplotypes

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • General Health & Medical Sciences (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • General Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Hospice & Palliative Care (AREA)
  • Biophysics (AREA)
  • Oncology (AREA)
  • Physics & Mathematics (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

This invention relates generally to the analytical testing of tissue samples in vitro, and more particularly to aspects of genetic polymorphisms and mutations of the PTK2B gene. The invention provides new PTK2B mutations and SNPs, useful in the diagnosis and treatment of subjects in need thereof. Accordingly, the various aspects of the present invention relate to polynucleotides encoding the PTK2B mutations of the invention, expression vectors encoding the PTK2B mutant polypeptides of the invention and organisms that express the PTK2B mutant and polymorphic polynucleotides and/or PTK2B mutant/polymorphic polypeptides of the invention. The various aspects of the present invention further relate to diagnostic/theranostic methods and kits that use the PTK2B mutations and polymorphisms of the invention to identify individuals predisposed to disease or to classify individuals with regard to drug responsiveness, side effects, or optimal drug dose.
PCT/US2007/003280 2006-02-09 2007-02-07 Mutations and polymorphisms of ptk2b Ceased WO2007095032A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US77177506P 2006-02-09 2006-02-09
US60/771,775 2006-02-09

Publications (2)

Publication Number Publication Date
WO2007095032A2 WO2007095032A2 (en) 2007-08-23
WO2007095032A3 true WO2007095032A3 (en) 2008-02-28

Family

ID=38050961

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2007/003280 Ceased WO2007095032A2 (en) 2006-02-09 2007-02-07 Mutations and polymorphisms of ptk2b

Country Status (1)

Country Link
WO (1) WO2007095032A2 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112695081B (en) * 2020-12-30 2022-08-26 中国医学科学院北京协和医院 New susceptibility gene of primary biliary cholangitis and application thereof

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030143606A1 (en) * 2000-06-30 2003-07-31 Alexander Olek Diagnosis of diseases associated with the immune system by determining cytosine methylation

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030143606A1 (en) * 2000-06-30 2003-07-31 Alexander Olek Diagnosis of diseases associated with the immune system by determining cytosine methylation

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
ANONYMOUS: "Kinase Variation Sequence Program", INTERNET ARTICLE, 2005, XP002448903, Retrieved from the Internet <URL:http://web.archive.org/web/20050205011923/http://agencourt.com/services/kinase> [retrieved on 20070901] *
DATABASE GENECARDS [online] 2007, "PTK2B protein tyrosine kinase 2 beta", XP002448904, Database accession no. PTK2B *
DATABASE SNP [online] 2003, "Cluster Report: rs1030526", XP002448905, Database accession no. rs1030526 *
LIU C ET AL: "SNP fine mapping of chromosome 8p21-12 reveals four potential candidate genes for schizophrenia, DPYSL2, TRIM35, PTK2B, and CHRNA2", AMERICAN JOURNAL OF MEDICAL GENETICS. PART B, NEUROPSYCHIATRIC GENETICS, WILEY-LISS, HOBOKEN, NJ, US, vol. 138B, no. 1, September 2005 (2005-09-01), pages 126, XP009088866, ISSN: 1552-485X *
NAYLOR TARA L ET AL: "High resolution genomic analysis of sporadic breast cancer using array-based comparative genomic hybridization", BREAST CANCER RESEARCH, CURRENT SCIENCE, LONDON, GB, vol. 7, no. 6, 24 November 2005 (2005-11-24), pages R1186 - R1198, XP021011919, ISSN: 1465-5411 *
STITZIEL NATHAN O ET AL: "A Protein Kinase Database for Genes Expressed in Human Bone Marrow: Application to Hematologic Malignancies.", BLOOD, vol. 100, no. 11, 16 November 2002 (2002-11-16), & 44TH ANNUAL MEETING OF THE AMERICAN SOCIETY OF HEMATOLOGY; PHILADELPHIA, PA, USA; DECEMBER 06-10, 2002, pages Abstract No. 2905, XP009088868, ISSN: 0006-4971 *

Also Published As

Publication number Publication date
WO2007095032A2 (en) 2007-08-23

Similar Documents

Publication Publication Date Title
WO2009132058A3 (en) Levels of bcma protein expression on b cells and use in diagnostic methods
WO2007016532A3 (en) Mutations and polymorphisms of hdac4
WO2005033652A3 (en) Methods for comparing relative flux rates of two or more biological molecules in vivo through a single protocol
MX2010006484A (en) Compositions and methods of detecting tiabs.
EP2667194A3 (en) Ratio based biomarkers and methods of use thereof
WO2006127861A3 (en) Diagnosis of diseases and conditions by analysis of histopathologically processed biological samples using liquid tissue preparations
NZ596614A (en) Diagnosis and treatment of alzheimer&#39;s disease
AU2002303444A1 (en) Detection of microsatellite instability and its use in diagnosis of tumors
WO2008122670A3 (en) Human diabetes susceptibility tnfrsf10b gene
WO2010028373A3 (en) Methods for diagnosing cancer and determining the overall survival and disease-free survival of cancer patients
WO2009065132A8 (en) Predicting and diagnosing patients with autoimmune disease
TW200711660A (en) Monitoring two dimensions of diabetes pathogenesis separately or concurrently (insulin sensitivity and beta-cell sufficiency): uses in diagnosis, prognosis, assessment of disease risk, and drug development
WO2006105252A3 (en) Diagnosis of chronic pulmonary obstructive disease and monitoring of therapy using gene expression analysis of peripheral blood cells
WO2008132763A3 (en) Genetic variants useful for risk assessment of coronary artery disease and myocardial infarction
SG171691A1 (en) Biomarkers for diagnosing multiple sclerosis, and methods thereof
WO2006130527A3 (en) Mutations and polymorphisms of fibroblast growth factor receptor 1
WO2009133197A3 (en) Levels of april in serum and use in diagnostic methods
WO2006110478A3 (en) Mutations and polymorphisms of epidermal growth factor receptor
WO2007022041A3 (en) Mutations and polymorphisms of hdac3
EP2287340A3 (en) Method for diagnosis and treatment of a mental disease
WO2007030455A3 (en) Mutations and polymorphisms of hdac10
WO2005015155A3 (en) Methods for comparing relative flux rates of two or more biological molecules in vivo through a single protocol
DE602006012995D1 (en) BREAST CANCER DIAGNOSTIC PROCEDURE
WO2007109183A3 (en) Mutations and polymorphisms of fms-related tyrosine kinase 1
WO2007038073A3 (en) Mutations and polymorphisms of hdac11

Legal Events

Date Code Title Description
NENP Non-entry into the national phase

Ref country code: DE

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 07750148

Country of ref document: EP

Kind code of ref document: A2

122 Ep: pct application non-entry in european phase

Ref document number: 07750148

Country of ref document: EP

Kind code of ref document: A2